Lung Cancer ESMO 2020 Expert Perspective and Strategic Insights
Expert perspectives and strategic insights on the latest therapeutic developments and translational research coming out of ESMO 2020 regarding lung cancer treatment. Main focus areas: immunotherapy in NSCLC and mesothelioma, oncogenic drivers, and small cell lung cancer
FACULTY CHAIR
Corey Langer, MD, FACP
University of Pennsylvania, US
Faculty Members
Benjamin Besse, MD, PhD
Institute Gustave Roussy, Villejuif, France
Julie Brahmer, MD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, US
Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
Marina Garassino, MD
Istituto Nazionale dei Tumori, Milan, Italy
Nasser Hanna, MD
Indiana University School of Medicine, Indianapolis, IN, US
Jyoti Patel, MD
Northwestern University, Evanston, IL, US
Solange Peters, MD, PhD
University Hospital of Lausanne, Switzerland
David Spigel, MD
Sarah Cannon Research Institute, Nashville, TN, US
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
The report includes recommendations and key takeaways on
- Immunotherapy in Stage I–III NSCLC
- Immunotherapy in Stage IV NSCLC
- Biomarkers for Immunotherapy in NSCLC
- EGFR Inhibition (resectable and metastatic NSCLC)
- Targeting Other Gene Mutations (BRAF, MET, HER2, KRAS)
- Targeting Gene Fusions (ALK, ROS1, RET, NTRK)
- Evolving Standards in SCLC
